Hot Pursuit     18-Jan-25
Gland Pharma gets EIR from USFDA for Pashamylaram facility
Gland Pharma announced that it has received an establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Pashamylaram facility at Hyderabad.
The Pashamylaram facility received an EIR, which indicates closure of the inspection, Gland Pharma said in a filing.

The USFDA inspected the facility between 25 July 2024 and 2 August 2024 for good manufacturing practices (GMP) and issued three Form 483 observations. These observations were procedural in nature.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

On a consolidated basis, the firm’s net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.10% to settle at Rs 1,678.95 on Friday, 18 January 2025.

Previous News
  Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods
 ( Market Commentary - Stock Alert 20-Jun-24   08:50 )
  Gland Pharma consolidated net profit rises 6.69% in the December 2024 quarter
 ( Results - Announcements 07-Feb-25   14:19 )
  Gland Pharma Ltd gains for fifth session
 ( Hot Pursuit - 11-Jun-24   13:00 )
  Volumes spurt at Symphony Ltd counter
 ( Hot Pursuit - 10-Jul-23   11:00 )
  Volumes spurt at Gland Pharma Ltd counter
 ( Hot Pursuit - 21-Jul-22   14:30 )
  Gland Pharma consolidated net profit declines 15.74% in the September 2024 quarter
 ( Results - Announcements 05-Nov-24   07:30 )
  Gland Pharma allots 2,400 equity shares under ESOS
 ( Corporate News - 26-Mar-24   09:55 )
  Gland Pharma skid after Q1 PAT drops 35% YoY to Rs 229 cr
 ( Hot Pursuit - 21-Jul-22   10:43 )
  Gland Pharma hits the roof after strong sequential performance
 ( Hot Pursuit - 08-Aug-23   10:47 )
  Gland Pharma Ltd leads gainers in 'A' group
 ( Hot Pursuit - 08-Aug-23   12:00 )
  Gland Pharma Ltd gains for fifth session
 ( Hot Pursuit - 05-Feb-24   13:00 )
Other Stories
  Shipping Corp Q3 PAT drops 44% YoY to Rs 76 cr
  08-Feb-25   15:44
  Honeywell Automation PAT rises 3% YoY to Rs 132 cr in Q3
  08-Feb-25   14:35
  Oil India Q3 PAT slides 23% YoY to Rs 1,222 crore
  08-Feb-25   13:01
  Delhivery Q3 PAT climbs 113% YoY to Rs 25 cr
  08-Feb-25   11:56
  LIC Q3 PAT rises 17% YoY to Rs 11,056 cr
  08-Feb-25   11:12
  Fortis Healthcare Q3 PAT climbs 84% YoY to Rs 248 cr
  08-Feb-25   08:59
  Balrampur Chini declines as Q3 PAT slides 23% YoY to Rs 70 crore
  07-Feb-25   16:55
  NOCIL slumps after Q3 PAT slips 57% YoY to Rs 13 crore
  07-Feb-25   16:15
  Bikaji Foods slides as Q3 PAT drops 39% YoY to Rs 29 cr
  07-Feb-25   15:35
  DCX Systems drops after Q3 PAT slides 25% YoY to Rs 10 crore
  07-Feb-25   15:34
Back Top